

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

February 13, 2015

<u>Via E-mail</u>
Mr. Barry Weiner
Chief Financial Officer
Enzo Biochem, Inc.
527 Madison Avenue
New York, NY 10022

Re: Enzo Biochem, Inc.

Form 10-K for the Fiscal Year Ended July 31, 2014

Filed October 9, 2014 File No. 001-09974

Dear Mr. Weiner:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/Tia L. Jenkins

Tia L. Jenkins Senior Assistant Chief Accountant Office of Beverages, Apparel, and Mining